Tenaya Therapeutics Holds 2024 Annual Meeting
Ticker: TNYA · Form: 8-K · Filed: May 31, 2024
Sentiment: neutral
Topics: corporate-governance, shareholder-meeting
TL;DR
Tenaya's shareholders voted on directors and auditors at the May 29th meeting.
AI Summary
On May 30, 2024, Tenaya Therapeutics, Inc. filed an 8-K report to announce the results of its 2024 Annual Meeting of Stockholders, which took place on May 29, 2024. The company's stockholders voted on several proposals, including the election of directors and the ratification of the appointment of its independent registered public accounting firm.
Why It Matters
This filing confirms the outcomes of shareholder votes, providing clarity on the company's leadership and financial oversight.
Risk Assessment
Risk Level: low — This is a routine corporate filing detailing the results of a shareholder meeting, with no immediate financial or operational risks indicated.
Key Players & Entities
- Tenaya Therapeutics, Inc. (company) — Registrant
- May 30, 2024 (date) — Date of Report
- May 29, 2024 (date) — Date of Annual Meeting
FAQ
What was the primary purpose of the May 30, 2024 8-K filing for Tenaya Therapeutics, Inc.?
The primary purpose was to report the results of the company's 2024 Annual Meeting of Stockholders held on May 29, 2024.
When did Tenaya Therapeutics, Inc. hold its 2024 Annual Meeting of Stockholders?
The 2024 Annual Meeting of Stockholders was held on May 29, 2024.
What types of proposals were voted on at the 2024 Annual Meeting?
The stockholders voted on proposals including the election of directors and the ratification of the appointment of the independent registered public accounting firm.
What is the principal executive office address for Tenaya Therapeutics, Inc.?
The address is 171 Oyster Point Boulevard, Suite 500, South San Francisco, CA 94080.
What is the telephone number for Tenaya Therapeutics, Inc.?
The telephone number is (650) 825-6990.
Filing Stats: 522 words · 2 min read · ~2 pages · Grade level 9.8 · Accepted 2024-05-31 16:13:56
Key Financial Figures
- $0.0001 — e on which registered Common Stock, $0.0001 par value per share TNYA The Nasdaq
Filing Documents
- tnya-20240530.htm (8-K) — 57KB
- 0000950170-24-067318.txt ( ) — 175KB
- tnya-20240530.xsd (EX-101.SCH) — 28KB
- tnya-20240530_htm.xml (XML) — 5KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. Tenaya Therapeutics, Inc. (the "Company") held its annual meeting of stockholders (the "Annual Meeting") on May 30, 2024. The matters voted upon at the Annual Meeting and the voting results for each proposal are set forth below. Proposal 1: Election of Class III Directors Name of Director Nominee For Withheld Broker Non-Votes Faraz Ali, M.B.A. 60,262,398 157,949 10,386,279 June Lee, M.D. 60,205,014 215,333 10,386,279 Deepak Srivastava, M.D. 53,643,731 6,776,616 10,386,279 Each director nominee was duly elected to serve until the 2027 annual meeting of stockholders and until their successor is duly elected and qualified, subject to earlier resignation or removal. Proposal 2: Ratification of the Appointment of Independent Registered Public Accounting Firm For Against Abstain Broker Non-Votes 70,778,448 16,045 12,133 0 The stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TENAYA THERAPEUTICS, INC. By: /s/ Leone D. Patterson, M.B.A. Leone D. Patterson, M.B.A. Chief Financial and Business Officer Date: May 31, 2024